WASHINGTON -- U.S. Vice-President Mike Pence will receive the coronavirus vaccine in public on Friday as the outgoing administration and President-elect Joe Biden's team try to build support for a mass inoculation to stanch the deadly pandemic.
Pence, who has headed the White House coronavirus task force, is poised to become the highest-profile recipient to date of a vaccine rolled out in the United States this week with hopes of curbing a virus that has killed more than 307,000 Americans.
Biden, set to take office on Jan. 20, will publicly get the vaccine next week, according to transition officials. At age 78, Biden is in the high-risk group for COVID-19, which has proven particularly dangerous among the elderly.
The Democrat has been building his incoming administration as he prepares for his inauguration, and will nominate Michael Regan, North Carolina's top environmental regulator, to head the Environmental Protection Agency, three sources with knowledge of the discussions said on Thursday.
Regan would be returning to Washington to lead an agency at which he previously worked under presidents of both parties. His nomination is still subject to a final vetting process, the sources said.
Biden has vowed to make the fight against the pandemic his top priority when he takes office. President Donald Trump, who Biden has accused of surrendering to the public health crisis, frequently downplayed the severity of the pandemic and feuded with top U.S. public health officials.
Trump will get the vaccine when his medical team decides it is best, according to the White House. The Republican president was hospitalized and received treatment in October after testing positive for COVID-19.
Pence's wife, Karen, and Surgeon General Jerome Adams also will get the vaccine on Friday, according to the White House.
Several European leaders were self-isolating on Thursday after French President Emmanuel Macron tested positive for the virus, prompting a track-and-trace effort following meetings by EU heads of government in recent days.
ANOTHER VACCINE
The vaccine, made by Pfizer Inc and German partner BioNTech SE, is expected to become widely available to the general public next year.
A panel of outside advisers to the U.S. Food and Drug Administration is expected to endorse emergency use of a second vaccine by Moderna Inc in a meeting on Thursday.
Many Americans remain skeptical. Only 61% of respondents in a Reuters/Ipsos poll, conducted from Dec. 2 to 8, said they were open to getting vaccinated.
That is short of the 70% level that public health officials have said is needed to reach herd immunity - achieved when a large portion of a given population is immune to a disease - either through exposure or vaccination. Roughly 5% of Americans are believed to have been infected by the novel coronavirus.
One health-care worker in Alaska experienced a severe allergic reaction after receiving the vaccine, officials said, in what is believed to be the only adverse reaction so far in the United States.
All over the United States, doctors, nurses and delivery people are wrestling with challenges in the vaccine rollout including delays, anxiety and keeping the vaccine at just the right level of cold.
Biden will inherit these logistical difficulties, as well as the task of persuading Americans to get the vaccine.
One of those tasked by Biden with building support, Dr. Marcella Nunez-Smith, told a Black civil rights group on Wednesday that the science was sound.
"The political interference risk was really, really removed," Nunez-Smith said on a call with the National Association for the Advancement of Colored People (NAACP), a civil rights group.
Reporting by Andy Sullivan and Trevor Hunnicutt; Additional reporting by Steve Gorman and Steve Holland; Writing by Sonya Hepinstall; Editing by Will Dunham, Noeleen Walder and Peter Cooney
